- Published
- 31 March 2020
- Journal article
Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement
- Authors
-
- Source
- Allergy
Full text
Abstract
Rights
http://onlinelibrary.wiley.com/termsAndConditions#vor http://doi.wiley.com/10.1002/tdm_license_1.1
Cite as
Bousquet, J., Akdis, C., Bachert, C., Klimek, L., Ansotegui, I., Bedbrook, A., Bosnic-Anticevich, S., Canonica, G., Chivato, T., Cruz, A., Czarlewski, W., Del Giacco, S., Du, H., Fonseca, J., Gao, Y., Haahtela, T., Hoffmann‐Sommergruber, K., Ivancevich, J., Khaltaev, N., Knol, E., Kuna, P., Larenas-Linnemann, D., Mullol, J., Naclerio, R., Ohta, K., Okamoto, Y., O'Mahony, L., Onorato, G., Papadopoulos, N., Pfaar, O., Samolinski, B., Schwarze, J., Toppila-Salmi, S., Ventura, M., Valiulis, A., Yorgancioglu, A., Zuberbier, T. & Pawankar, R. 2020, 'Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement', Allergy, 75(10), pp. 2440-2444. https://doi.org/10.1111/all.14302